New Approaches, New Hope
IL-12 TAVO
INVESTIGATIONAL INTRATUMORAL
CANCER IMMUNOTHERAPY

“I was headed down a one-way street with a dead end.”

Fran’s Story:
Reclaiming Independence from Melanoma

Clinical trials of today may power the medical advances of tomorrow

Learn more about our current clinical trials:

MerckAdvanced Melanoma

Triple Negative Breast Cancer

Tavokinogene Telseplasmid “TAVO” IL-12

Designed to take the fight directly to the tumor

We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.

Learn More

Designed to Arm the Immune System to Fight Cancer

Clinical Pipeline

Pipeline
Our core technology platform continues to advance through clinical trials for various cancers.

Learn More

Technology

Technology
The Intratumoral IL-12 platform is designed to boost the immune system to recognize and attack tumors.

Learn More

Collaborators

Collaborators
OncoSec continues to establish relationships with industry leaders to further advance our research.

Learn More